目的 探究孕三烯酮与亮丙瑞林联合治疗子宫内膜异位症（EMs）疗效及对性激素、炎症指标及糖类抗原125（CA125）、抗子宫内膜抗体（EMAb）、抗苗勒氏管激素（AMH）的影响。 方法 选取2019年11月至2022年11月医院收治的120例EMs患者，按随机数字表法将患者分为对照组（n = 60）与研究组（n = 60），对照组患者使用孕三烯酮治疗，研究组患者在对照组基础上加用亮丙瑞林治疗。观察两组患者治疗6个月后临床疗效，治疗前、治疗6个月后性激素指标［雌二醇（E₂）、促黄体生成激素（LH）、卵泡刺激素（FSH）］、炎症指标［白细胞介素-6（IL-6）、IL-8、肿瘤坏死因子α（TNF-α）、超敏C反应蛋白（hs-CRP）］、血清相关指标（CA125、EMAb、AMH），并记录用药期间患者药物不良反应发生情况及随访期间复发情况。 结果 经过6个月治疗后，研究组展示出的治疗总有效率达到91.67%，显著高于对照组治疗有效率为76.67%（P < 0.05）。治疗6个月后，两组患者E₂、LH、FSH、IL-6、IL-8、TNF-α、hs-CRP、CA125、EMAb水平较治疗前显著下降而AMH水平上升（P < 0.05），且研究组上述指标与同期对照组对比差异有统计学意义（P < 0.05）。统计分析结果显示，研究组数据相较于对照组差异有统计学意义（P < 0.05）。但两组患者在6个月药物治疗中的不良反应发生率，以及停药后2年内的疾病复发率，差异均无统计学意义（P > 0.05）。 结论 应用孕三烯酮联合亮丙瑞林治疗EMs患者效果显著，可显著改善患者内分泌状况，减轻炎症反应，改善血清生物标志物，安全性较高。

Objective To explore the efficacy of gestrinone combined with leuprolide in the treatment of endometriosis （EMs） and its effects on sex hormones， inflammatory indicators and peripheral blood carbohydrate antigen 125 （CA125）， endometrial antibody （EMAb） and anti-Müllerian hormone （AMH）. Methods 120 patients with EMs admitted to our hospital from November 2019 to November 2022 were selected. All patients were divided into control group and study group according to the random number table method， with 60 cases in each group. Control group was treated with gestrinone， and study group was additionally given leuprolide on the basis of control group. The clinical efficacy after 6 months of treatment， sex hormones indicators ［estradiol （E₂）， luteinizing hormone （LH）， follicle stimulating hormone （FSH）］， inflammatory indicators ［interleukin-6 （IL-6）， IL-8， tumor necrosis factor α （TNF-α）， hypersensitivity C-reactive protein （hs-CRP）］ and serum-related indicators （CA125， EMAb， AMH） before treatment and after 6 months of treatment were compared between the two groups， and the occurrence of adverse drug reactions during medication. Results After 6 months of treatment， the total effective rate of treatment in study group was significantly higher than that in control group （91.67% vs. 76.67%） （P < 0.05）. After 6 months of treatment， the levels of E₂， LH， FSH， IL-6， IL-8， TNF-α， hs-CRP， CA125 and EMAb in the two groups were significantly decreased compared with those before treatment while the level of AMH was increased （P < 0.05）， and the above indexes in study group were significantly different from those in control group during the same period （P < 0.05）. During 6 months of medication， there were no differences in the incidence rates of adverse drug reactions between the two groups （P > 0.05）. Conclusion Gestrinone combined with leuprolide has a significant effect in the treatment of patients with endometriosis， and it can significantly improve the endocrine， relieve inflammatory response and improve serum-related indicators， and it has high safety and good application value.